Efficacy and safety of recaticimab in lowering atherogenic lipids in patients with and without coronary artery disease: a patient-level pooled analysis
Patients with coronary artery disease (CAD) are at very high risk of recurrent cardiovascular events and require intensive lipid-lowering therapy to achieve guideline-recommended targets. Recaticimab is a long-acting anti-PCSK9 monoclonal antibody that has demonstrated significant lipid-lowering efficacy in patie...